Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 31, 2017

TiGenix begins enrolment in Phase Ib/IIa trial of Cx611 to treat severe sepsis

Belgium-based bio-pharmaceutical company TiGenix has begun enrolment for its Phase Ib/IIa clinical trial of Cx611 (SEPCELL) to treat severe sepsis in patients with community-acquired pneumonia (CAP).

Belgium-based bio-pharmaceutical company TiGenix has begun enrolment for its Phase Ib/IIa clinical trial of Cx611 (SEPCELL) to treat severe sepsis in patients with community-acquired pneumonia (CAP).

Cx611 is an intravenously administered product of allogeneic expanded adipose-derived stem cells (eASCs) designed to modulate and restore the deregulated immune response in patients with severe community-acquired pneumonia.

The multicentre, international Phase Ib/IIa trial will evaluate the Cx611 safety profile at 90 days, the decrease in the duration of mechanical ventilation and / or vasopressors, as well as the overall survival rate, clinical cure, and other efficacy-related endpoints.

TiGenix chief medical officer Marie Paule Richard said: "Cx611, with its immunomodulatory action, represents a novel approach to address severe sepsis.

"The SEPCELL trial will provide valuable information on the safety, tolerability and efficacy of Cx611 as a candidate for the treatment of patients with severe sepsis."

"The SEPCELL trial will provide valuable information on the safety, tolerability and efficacy of Cx611 as a candidate for the treatment of patients with severe sepsis."

Sepsis is a condition that arises when the body injures its own tissues and organs in response to an infection.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The trial is expected to enrol 180 patients and will be conducted in multiple European centres in patients with severe community-acquired bacterial pneumonia, admitted to intensive care units due to severe sepsis.

It is claimed to have been designed to address the drawbacks of previous trials with precise inclusion and exclusion criteria, as well as a specific patient population.

Represented by a group of five European research institutes in addition to TiGenix, the SEPCELL project has received a grant of €5.4m from the European Union.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU